Recon: Senate Scrambles After Coronavirus Stimulus Stalls Sunday; FDA Rejects Lilly’s Jardiance for Type 1 Diabetes

• Trump Says Coronavirus Cure Cannot ‘Be Worse Than the Problem Itself’ (NYTimes) (Reuters)
• Coronavirus stimulus bill fails to move forward; McConnell cites 'obstruction' (NBC) (Vox)
• Senate scrambles to finish coronavirus package by end of day (Politico) (The Hill)
• Coronavirus forces states to order nearly one in three Americans to stay home (Reuters)
• FDA Lifts Import Curbs on Maker of Unproven Virus Drug in India (Bloomberg)
• FDA is working on treatment for coronavirus with blood from recovered patients (NBC)
• Trump’s Embrace of Unproven Drugs to Treat Coronavirus Defies Science (NYTimes)
• States work to limit prescriptions of potential coronavirus drugs (Reuters)
• Roche gets FDA nod for trial to test arthritis drug on coronavirus patients (Reuters) (Press)
• Roche CEO says broad coronavirus testing will take weeks: CNBC (Reuters)
• Healthcare group Novacyt wins US approval for coronavirus test (Reuters)
• Eli Lilly to delay new studies due to coronavirus outbreak (Reuters) (Endpoints)
• No surprise: After near unanimous adcomm, FDA rejects Eli Lilly bid to bring Jardiance to type 1 patients (Endpoints)
• Rand Paul becomes first US senator to test positive for coronavirus (Reuters) (The Hill)
• Trump rejects calls to directly use Defense Production Act (The Hill) (ProPublica)
• White House $46 billion emergency request balloons to $242 billion in Senate coronavirus stimulus talks (The Hill)

• Global coronavirus cases cross 350,000, death toll passes 15,000 as pandemic takes hold (CNBC)
• UN to create global coronavirus fund, Norway says (Reuters)
• Lockdowns not enough to defeat coronavirus: WHO's Ryan (Reuters)
• WHO launches global megatrial of the four most promising coronavirus treatments (Science Mag)
• U.K. Watchdog Warns Pharmaceutical, Food Industries Against Exploiting Coronavirus (WSJ)
• India to Spend $1.3 Billion to Boost Pharmaceutical Production (Bloomberg)
• South Korea reports fewest new coronavirus cases since February 29 peak (Reuters)
• AbbVie waives all worldwide restrictions on making generic copies of its Kaletra HIV pill (STAT)
• Nigeria records chloroquine poisoning after Trump endorses it for coronavirus treatment (CNN)
• UK's Smiths makes ventilator available to other producers (Reuters)
• Back to China: companies see a safe haven emerging as the virus takes over the rest of the world (BioCentury)

• Warmer Weather May Slow, but Not Halt, Coronavirus (NYTimes)
• Race to find treatment using re-engineered medicines (Financial Times)
• Scientists Identify 69 Drugs to Test Against the Coronavirus (NYTimes)
• Lost Sense of Smell May Be Peculiar Clue to Coronavirus Infection (NYTimes)
• The Best-Case Outcome for the Coronavirus, and the Worst (NYTimes)
• The virus can be stopped, but only with harsh steps, experts say (NYTimes)
• New York coronavirus cases surge 38% overnight to 20,875 (CNBC)
• NY Will Start Using Trial Drugs on Tuesday to Treat Patients (Bloomberg)
• Ohio, Louisiana, Delaware Order Residents To Stay Home As Cases Of COVID-19 Rise (NPR)
• COVID-19: EU institutions take action to procure life-saving medical equipment (Europarl)
• CDC Coronavirus Testing Decision Likely To Haunt Nation For Months To Come (KHN)
• U.S. axed CDC expert job in China months before virus outbreak (Reuters)
• Government watchdog launches review into HHS' coronavirus response (CNN)
• A Onetime Germ-Warfare Site Is Army’s Front Line in Coronavirus Battle (WSJ)
• 'A slow burn': Coronavirus symptoms often linger before worsening (NBC)
• Former FDA head: 'Life's never going to be perfectly normal until we get to a vaccine' (The Hill)
• Britain now has access to 12,000 ventilators: health minister (Reuters)
• Cuban doctors head to Italy to battle coronavirus (Reuters)
• Germany's infection curve could be flattening off, public health chief says (Reuters)
• Germany reports 22,672 coronavirus cases, 86 deaths (Reuters)
• Spain's coronavirus death toll adds 462 overnight - health ministry (Reuters)
• Spain to treat thousands of coronavirus patients in conference hall as toll tops 1,000 (Reuters)
• Canada coronavirus death toll jumps, officials could punish those ignoring precautions (Reuters)
• India shuts down flights, big cities as coronavirus toll rises in region (Reuters)
• Turkey threatens to seize factories unless they sell masks to government (Reuters)
• Honeywell, 3M to ramp up N95 face masks production (MassDevice)
• AlloVir, Baylor ally to develop COVID-19 T-cell therapy (Fierce)
• Bioneer Receives CE Mark for Coronavirus Kits, Inks Supply Agreement With Romania (Genomeweb)
• Fiat Chrysler CEO says group to produce face masks in Asia: union representative (Reuters)
• Releasing inmates, screening staff: U.S. jails and prisons rush to limit virus risks (Reuters)
• UK scientists to track mutations in coronavirus to map spread (Reuters)
• Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn’s Leronlimab, Bringing the Total to Four Patients (Press)
• No evidence to support intravenous high-dose vitamin C in the management of COVID-19 (TGA)

• Lupus Patients Can’t Get Crucial Medication After President Trump Pushes Unproven Coronavirus Treatment (ProPublica)
• Covid-19 is reshaping the world of bioscience publishing (STAT)
• As Covid-19 spreads, disruptions to clinical trial and drug development accelerate (STAT)
• ADAPTABLE: The Future of Big Clinical Trial Design? (Medpage)
• Heartburn Drugs Tied to Bone Fractures in Children (NYTimes)
• Thalidomide Use Did Happen Here, These Americans Say (NYTimes)
• The Story of Thalidomide in the U.S., Told Through Documents (NYTimes)
• The unseen survivors of thalidomide want to be heard (NYTimes)
• Boehringer kicks back unwanted Amylin analog drug work to Zealand Pharma (Fierce)
• Startup Spotlight: Carisma Therapeutics wants to make a cell therapy that will work in solid tumors (STAT)
• Bayer inks up with “small” Indian biotech for new approach at an old target (Endpoints) (Economic Times)

• AbbVie, Roche's Venclexta nails confirmatory combo trial in AML after flopping earlier study  (Fierce) (Press)
• Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency (Press)

• RaySearch Labs issues urgent field safety notice for certain RayStations (MassDevice)
• Canon Medical Receives FDA Clearance for Compressed SPEEDER Technology for 3T MR System (Press)

• Coronavirus Product Communications Would Get Safe Harbor Under Senate Bill (Pink Sheet-$)
• Antibiotics May Finally Get Better Medicare Payments Under US Senate COVID-19 Aid Package (Pink Sheet-$)
• Senators Who Led Pro-Pharma Patent Reform Get Drugmaker Cash (KHN)
• Chugai sues Fresenius Kabi in the USA for patent infringement (Pharmaletter)
• Calif. Pay-For-Delay Ban Hurts Pharma Cos., 9th Circ. Told (Law360-$)
• PTAB Axes Bulk Of Possible Cancer Treatment Patent In PGR (Law360-$)
• Shkreli-Founded Co. Defends Its Handling Of Life-Saving Drug (Law360-$)
• On Promoting Off-Label Use (Drug & Device Law)
• Preemption (and Some Other) Lessons from Amiodarone Litigation (Drug & Device Law)
• Bayer mediator says glyphosate settlement talks slowed by coronavirus (Reuters)

• The MDCG guidance on significant changes – a significant change? (medicaldeviceslegal)
• BIA welcomes UK government’s R&D tax credit cap amendment (Pharmaletter)
• Pharma industry rejoices as German court slams down Unified Patent Court system (Pharmaletter)
• Regulatory approval for Coronavirus (COVID-19) test kits (MHRA)
• Specification for ventilators to be used in UK hospitals during the coronavirus (COVID-19) outbreak (MHRA)

• India to spend $1.3 billion to boost pharmaceutical production (Economic Times)
• DCGI to fast-track approval for Covid-19 drug, vaccine (Economic Times)
• Coronavirus: ICMR recommends hydroxychloroquine for high-risk population (Economic Times)
• Bengaluru based Skanray starts work on new ventilator design that would speed up production locally (Economic Times)

• In the shadow of Ebola and Covid-19, measles rips through Congo (Reuters)